eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone

SAN DIEGO, July 27, 2018 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company’s oral, small molecule inhibitor of MNK1/2, added on to patients already receiving an FDA-approved anti-PD-1 or anti-PD-L1 checkpoint inhibitor.

eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma

SAN DIEGO, June 6, 2018 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in the Phase 2 expansion portion of its monotherapy trial of eFT508, the company’s oral, small molecule inhibitor of MNK1/2, for the treatment of relapsed, refractory non-germinal center B cell (non-GCB) diffuse large B cell lymphoma (DLBCL).

eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer

 SAN DIEGO, May 11, 2018 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in the randomized portion of its Phase 2 clinical trial of eFT508, the company’s lead product candidate, in combination with avelumab*, an anti-PD-L1 checkpoint inhibitor, for the treatment of microsatellite stable colorectal cancer (MSS CRC). eFT508 is an oral, small molecule inhibitor of MNK1/2. The company also announced that it has selected 200 mg twice daily delivered orally as its dose for its Phase 2 clinical program of eFT508, both as a monotherapy and in combination with immune checkpoint inhibitors.

eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry

SAN DIEGO, April 26, 2018 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that research describing the atom by atom design and biological profile of the company’s lead product candidate eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, has been published in the Journal of Medicinal Chemistry.

eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting

SAN DIEGO, April 16, 2018 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a podium presentation on the structure and discovery of eFT226, a novel, potent and selective small molecule inhibitor of eukaryotic initiation factor 4A (eIF4A) at the American Association for Cancer Research (AACR) Annual Meeting held in Chicago this week.

eFFECTOR Announces Appointment of John W. Smither to its Board of Directors

SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the appointment of John W. Smither to the company’s board of directors.

Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile

SAN DIEGO, December 11, 2017– eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that data presented in a poster session at the American Society of Hematology (ASH) 59th Meeting and Annual Exhibition demonstrate clinical activity, including one partial response, for the company’s lead product candidate, eFT508. 

eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects

SAN DIEGO, November 10, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a poster presentation of preclinical data for its lead product candidate, eFT508, that defines its immunological mechanism of action and activation of anti-tumor immune response. 

eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer

SAN DIEGO, October 4, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has initiated dosing in a Phase 2 clinical study of eFT508 in combination with avelumab* in microsatellite stable colorectal cancer (MSS CRC). The trial (NCT03258398) is being conducted […]

eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

SAN DIEGO, July 24, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators for the treatment of cancer, today announced that the company has raised $38.6M in Series C financing. Pfizer Venture Investments (PVI) led the round and was joined by additional new investors including Alexandria Venture Investments. All existing investors […]